[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX348041B - Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide. - Google Patents

Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide.

Info

Publication number
MX348041B
MX348041B MX2015006104A MX2015006104A MX348041B MX 348041 B MX348041 B MX 348041B MX 2015006104 A MX2015006104 A MX 2015006104A MX 2015006104 A MX2015006104 A MX 2015006104A MX 348041 B MX348041 B MX 348041B
Authority
MX
Mexico
Prior art keywords
formulation
corticosteroid
formulation containing
sulfoalkyl ether
ether cyclodextrin
Prior art date
Application number
MX2015006104A
Other languages
English (en)
Inventor
Gerold L Mosher
Diane O Thompson
Rupert O Zimmerer
James D Pipkin
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of MX348041B publication Critical patent/MX348041B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una formulación inhalable que contiene una SAE-CD y un corticosteroide. La formulación está adaptada para la administración a un sujeto por medio de la nebulización con cualquier nebulizador conocido. La formulación se puede incluir en un equipo. La formulación es administrada como una solución acuosa, sin embargo, se puede almacenar como un polvo seco, solución lista para utilizarse o composición concentrada. La formulación se emplea en un sistema de nebulización mejorado para administrar un corticosteroide por medio de la inhalación. La SAE-CD presente en la formulación mejora significativamente la estabilidad química de la budesonida. Se proporciona un método para administrar la formulación por medio de la inhalación. La formulación también se puede administrar por medio de un aparato convencional para el suministro nasal.
MX2015006104A 2003-12-31 2004-12-31 Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide. MX348041B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53362803P 2003-12-31 2003-12-31
PCT/US2005/000082 WO2005065435A2 (en) 2003-12-31 2004-12-31 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

Publications (1)

Publication Number Publication Date
MX348041B true MX348041B (es) 2017-05-25

Family

ID=34794240

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA06007581A MXPA06007581A (es) 2003-12-31 2004-12-31 Formulacion inhalante que contiene eter sulfoalquilico-ciclodextrina y un corticosteroide.
MX2015006104A MX348041B (es) 2003-12-31 2004-12-31 Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA06007581A MXPA06007581A (es) 2003-12-31 2004-12-31 Formulacion inhalante que contiene eter sulfoalquilico-ciclodextrina y un corticosteroide.

Country Status (15)

Country Link
EP (4) EP3238708A1 (es)
JP (6) JP2007517069A (es)
KR (3) KR20070007076A (es)
CN (3) CN1976679B (es)
AU (3) AU2004312095A1 (es)
BR (3) BRPI0418276B8 (es)
CA (3) CA2551749C (es)
DK (1) DK1732512T3 (es)
HU (1) HUE032527T2 (es)
IL (6) IL176575A0 (es)
MX (2) MXPA06007581A (es)
NZ (1) NZ548225A (es)
PT (1) PT1732512T (es)
RU (3) RU2388462C2 (es)
WO (3) WO2005065435A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CA2562585A1 (en) 2004-04-23 2005-11-10 Cydex, Inc. Dpi formulation containing sulfoalkyl ether cyclodextrin
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
JP5465432B2 (ja) * 2005-10-26 2014-04-09 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物及びその製造方法
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
JP2009516001A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤とシクロデキストリンとを含む組成物
WO2007072497A2 (en) * 2005-12-02 2007-06-28 Alembic Limited Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
JP2009520827A (ja) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー 肺内沈着の増大を有するコルチコステロイドを送達するためのシステムおよび方法
DK1971369T3 (da) * 2005-12-21 2009-11-16 Meda Pharma Gmbh & Co Kg Kombination af R,R-glycopyrrolat, rolipram og budesonid til behandling af inflammatoriske sygdomme
TR201807714T4 (tr) * 2006-02-10 2018-06-21 Pari Pharma Gmbh İnhalasyon tedavisine yönelik nebülize antibiyotikler.
WO2007095342A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Stable corticosteroid mixtures
DK2010220T3 (da) * 2006-04-03 2022-05-23 Ceva Animal Health Pty Ltd Stabiliserede pentosanpolysulfat-(pps)-formuleringer
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1894559A1 (en) * 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
WO2008047149A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
WO2008065142A1 (en) * 2006-11-29 2008-06-05 N.V. Organon Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
CA2705159A1 (en) * 2007-11-09 2009-05-14 Map Pharmaceuticals, Inc. Methods for administering corticosteroid formulations
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
JP5654498B2 (ja) * 2009-02-25 2015-01-14 スプラテック ファーマ インコーポレイテッド ベンダムスチン環状多糖組成物
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
KR101991367B1 (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
MX350163B (es) 2009-05-29 2017-08-29 Pearl Therapeutics Inc Composiciones para suministro respiratorio de agentes activos y metodos y sistemas asociados.
PL3278809T3 (pl) 2009-06-18 2020-06-15 Serenity Pharmaceuticals Llc Bezpieczne podawanie desmopresyny
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RU2445119C2 (ru) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Фармацевтическая композиция и способ ее ингаляционного введения
RU2605849C2 (ru) * 2011-04-26 2016-12-27 Фектура Гмбх Введение илопроста в виде аэрозольных болюсов
CN102188371B (zh) * 2011-05-11 2013-01-23 台州职业技术学院 一种环索奈德纳米粒水溶液及其制备方法
CN102973574A (zh) * 2011-09-02 2013-03-20 北京燕锋晨医药技术发展有限公司 一种用于治疗哮喘的药物组合物及制备方法
PT3517541T (pt) 2012-05-08 2020-08-28 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
KR20190137963A (ko) * 2012-05-08 2019-12-11 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2506080C1 (ru) * 2012-09-25 2014-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО НижГМА Минздравсоцразвития России) Способ лечения и профилактики осложнений в полости рта, вызванных приемом ингаляционных гормональных препаратов у больных бронхиальной астмой
RU2493827C1 (ru) * 2012-10-03 2013-09-27 Шолекс Девелопмент Гмбх Стабильный комбинированный раствор фенотерола гидробромида и ипратропия бромида
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP4122469A1 (en) * 2014-03-28 2023-01-25 Paul Maes Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
WO2016131051A1 (en) * 2015-02-13 2016-08-18 Vanderbilt University Milrinone composition and method for administering same
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
WO2017193110A1 (en) * 2016-05-06 2017-11-09 Stites Adam Cannabinoid compositions for sublingual spray nebulizer
UY37269A (es) 2016-06-02 2018-01-02 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
LT3658192T (lt) 2017-12-01 2021-07-12 Abbvie Inc. Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai
WO2019147154A1 (ru) * 2018-01-23 2019-08-01 Александр Григорьевич ЧУЧАЛИН Фармацевтическая композиция (варианты) применение фармацевтической композиции (варианты)
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20220031712A1 (en) * 2020-06-23 2022-02-03 Cai Gu Huang Preparation of a pharmaceutical composition of olodaterol and budesonide
US20210393521A1 (en) * 2020-06-23 2021-12-23 Cai Gu Huang Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
CN113018280A (zh) * 2021-03-01 2021-06-25 石家庄四药有限公司 一种异丙托溴铵吸入用溶液制剂及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008875A (en) * 1960-01-08 1961-11-14 Upjohn Co Neomycin and mirystyl-gamma-picolinium halide compositions
NL289785A (es) * 1962-11-29
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5510339A (en) 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
ATE241984T1 (de) 1993-03-26 2003-06-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE69530519T2 (de) 1994-12-22 2004-03-04 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
AU4717997A (en) * 1996-10-28 1998-05-22 Farmarc Nederland Bv Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE69834154T2 (de) 1997-07-01 2007-01-25 Pfizer Products Inc., Groton Verfahren zur Herstellung von einem Cyclodextrin
AU2081999A (en) 1998-01-13 1999-08-02 Astrazeneca Uk Limited Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
FR2789685B1 (fr) 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
IL149085A0 (en) 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
DE60117777T2 (de) 2000-05-11 2006-08-17 Eastman Chemical Co., Kingsport Acylierte zyclodextrin guest-inklusion komplexe
JP2005503446A (ja) 2001-01-11 2005-02-03 イーストマン ケミカル カンパニー シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
DE60211132T2 (de) 2001-02-14 2006-09-28 Akzo Nobel N.V. 2-alkylierte cyclodextrin-derivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
KR20050051686A (ko) 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도

Also Published As

Publication number Publication date
IL176577A0 (en) 2006-10-31
CN1976679A (zh) 2007-06-06
EP1732512B1 (en) 2017-03-22
WO2005065649A1 (en) 2005-07-21
IL176575A0 (en) 2006-10-31
IL176576A0 (en) 2006-10-31
EP1732512A2 (en) 2006-12-20
WO2005065435A3 (en) 2005-09-01
BRPI0418276B1 (pt) 2017-02-14
CA2551749A1 (en) 2005-07-21
CN1921830A (zh) 2007-02-28
CA2552641A1 (en) 2005-07-21
PT1732512T (pt) 2017-07-24
JP2007517067A (ja) 2007-06-28
CN1921834A (zh) 2007-02-28
WO2005065651A1 (en) 2005-07-21
NZ548225A (en) 2012-12-21
JP6186478B2 (ja) 2017-08-23
AU2004312095A1 (en) 2005-07-21
AU2004311478A1 (en) 2005-07-21
CA2551826A1 (en) 2005-07-21
MXPA06007581A (es) 2007-03-09
RU2006127432A (ru) 2008-02-10
HUE032527T2 (en) 2017-09-28
EP1718276A4 (en) 2008-07-23
EP1732512A4 (en) 2008-07-23
IL225946A0 (en) 2013-06-27
EP1729724A1 (en) 2006-12-13
EP1718276A2 (en) 2006-11-08
BRPI0418276B8 (pt) 2021-05-25
IL225946A (en) 2017-04-30
RU2388462C2 (ru) 2010-05-10
JP5782413B2 (ja) 2015-09-24
KR20070005586A (ko) 2007-01-10
CA2551749C (en) 2014-02-11
EP1729724A4 (en) 2008-07-23
JP2007517069A (ja) 2007-06-28
BRPI0418276A (pt) 2007-05-02
IL251496B (en) 2021-04-29
CN1976679B (zh) 2011-08-31
KR20070007076A (ko) 2007-01-12
JP2015129173A (ja) 2015-07-16
BRPI0418232A (pt) 2007-04-27
AU2004312096A1 (en) 2005-07-21
JP2012224648A (ja) 2012-11-15
KR20070007075A (ko) 2007-01-12
WO2005065435A2 (en) 2005-07-21
IL251496A0 (en) 2017-05-29
DK1732512T3 (en) 2017-07-10
RU2006127467A (ru) 2008-02-10
RU2390330C2 (ru) 2010-05-27
JP2007517068A (ja) 2007-06-28
EP3238708A1 (en) 2017-11-01
JP2016172774A (ja) 2016-09-29
RU2006127443A (ru) 2008-02-10
BRPI0418386A (pt) 2007-05-22

Similar Documents

Publication Publication Date Title
MX348041B (es) Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide.
WO2008005692A3 (en) INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID
AU2017228051B2 (en) Nicotine formulation and aerosols
NZ597354A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
RS76604A (en) Pressuriesed metered dose inhalers containing solutions of beta-2 agonists
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
CN101606903A (zh) 一种氨溴索的雾化吸入用溶液剂及其制备方法
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AR052759A1 (es) Dispositivo inhalador de medicamentos
BR112014008609A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, método para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
CN109771398B (zh) 一种帕拉米韦溶液型吸入剂及其制备方法
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
CN103462942A (zh) 一种吸入用盐酸氨溴索溶液
TWI488656B (zh) 妥布黴素調配物
NZ600208A (en) Inhalation solutions
JP2023547040A (ja) ピロロピリジン－アニリン化合物による、認知機能不全の処置方法
CN106667974A (zh) 一种吸入用硫酸特布他林溶液制备方法
WO2010025505A1 (en) Analgesia by transmucosal administration
WO2013137009A1 (ja) 慢性閉塞性肺疾患改善剤
McPeck Improved aerosol drug delivery with an electronic mesh nebulizer during non-invasive ventilation
CN201267665Y (zh) 呼吸机辅助雾化器
Kadrichu et al. In vitro efficiency of the Amikacin Inhale System, a novel integrated drug-device delivery system
CN203043243U (zh) 一种有利于重症患者呼吸的干氧驱动雾化器之构件
CN209060233U (zh) 一种液体定量微颗粒吸入器
WO2021151005A9 (en) Inhaled das181 to treat cancer in the lung